Swedish biotechnology company Active Biotech AB (STO:ACTI) on Monday provided an update on its clinical phase Ib/IIa study of tasquinimod in relapsed refractory multiple myeloma (RRMM) patients.
The study is ongoing at the Abramson Cancer Center, University of Pennsylvania. Data from 11 patients treated with tasquinimod in combination with ixazomib, lenalidomide and dexamethasone (IRd) shows no unexpected toxicity and good tolerability.
Three patients demonstrated clinical benefit, including one partial response and two minimal responses, among nine patients refractory to prior proteasome inhibitor and immunomodulatory drug regimens. The study aims to enrol up to six additional patients refractory to their most recent proteasome inhibitor/immunomodulatory drug combination.
Principal investigator Dr Dan Vogl highlighted the clinically meaningful disease responses in highly refractory patients, suggesting tasquinimod's potential to overcome treatment resistance and improve myeloma therapies.
Merck discontinues Phase 3 trials KEYNOTE-867 and KEYNOTE-630
Oncosure introduces Rapid Cancer Screening Test
Bayer and NextRNA collaborate on LncRNA-targeting therapeutics
GSK welcomes Delaware Supreme Court review of Zantac litigation
Fusion Antibodies expands collaboration with US National Cancer Institute
Telix Pharmaceuticals submits TLX101-CDx NDA to US FDA
Astellas initiates Phase 3 study for fezolinetant in breast cancer patients
Cantargia updates clinical trial timelines for nadunolimab
RedHill Biopharma's Opaganib receives US FDA orphan-drug designation